Microalbuminuria - A new cardiovascular risk factor?;Mikroalbuminurie - Ein neuer marker für kardiovaskuläres risiko?

Therapeutische Umschau

Volumn 63, Issue 9, 2006, Pages 565-568

  Huynh Do, U ^a   Eisenberger, Ute ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ACTIVITY; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; MICROALBUMINURIA; PREDICTION; RENAL PROTECTION; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; INCIDENCE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 33749152297     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.63.9.565     Document Type: Review

References (12)

1. Becker GJ. Which albumin should we measure? Kidney Int Suppl 2004(92): S16-7.
2. Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18(4): 572-81.
3. Busby DE, Bakris GL. Comparison of commonly used assays for the detection of microalbuminuria. J Clin Hypertens (Greenwich) 2004; 6(11 Suppl 3): 8-12.
4. Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988; 296(6616): 156-60.
5. Ibsen H, Wachtell K, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Kidney Int Suppl 2004(92): S56-8.
6. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356(9227): 366-72.
7. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106(14): 1777-82.
8. de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 2004(92): S2-6.
9. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67(3): 799-812.
10. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861-9.
11. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995-1003.
12. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110(18): 2809-16.